A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04175613 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
160
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen